Cargando…

Gene Expression Signature Associated with Clinical Outcome in ALK-Positive Anaplastic Large Cell Lymphoma

SIMPLE SUMMARY: Anaplastic large cell lymphomas associated with ALK translocation have a good outcome after CHOP treatment; however, the 2-year relapse rate remains at 30%. Microarray gene-expression profiling, high throughput RT-qPCR, and RNA sequencing of 48 ALK-positive anaplastic large cell lymp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daugrois, Camille, Bessiere, Chloé, Dejean, Sébastien, Anton-Leberre, Véronique, Commes, Thérèse, Pyronnet, Stephane, Brousset, Pierre, Espinos, Estelle, Brugiere, Laurence, Meggetto, Fabienne, Lamant, Laurence
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582782/ https://www.ncbi.nlm.nih.gov/pubmed/34771686 http://dx.doi.org/10.3390/cancers13215523

Ejemplares similares

Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death
por: Torossian, Avedis, et al.
Publicado: (2019)

Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma
por: Mitou, Géraldine, et al.
Publicado: (2015)

Doxorubicin-induced loss of DNA topoisomerase II and DNMT1- dependent suppression of MiR-125b induces chemoresistance in ALK-positive cells
por: Congras, Annabelle, et al.
Publicado: (2018)

miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells
por: Hoareau-Aveilla, Coralie, et al.
Publicado: (2019)

Non-Coding RNA Networks in ALK-Positive Anaplastic-Large Cell Lymphoma
por: Fuchs, Steffen, et al.
Publicado: (2019)

P1166: BRIGATINIB IN PATIENTS WITH ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA WHO HAVE FAILED BRENTUXIMAB VEDOTIN
por: Veleanu, Layla, et al.
Publicado: (2023)

A novel leukemic route of mutant NPM1 through nuclear import of the overexpressed long noncoding RNA LONA
por: Gourvest, Morgane, et al.
Publicado: (2021)

High Levels of miR-7-5p Potentiate Crizotinib-Induced Cytokilling and Autophagic Flux by Targeting RAF1 in NPM-ALK Positive Lymphoma Cells
por: Sorrentino, Domenico, et al.
Publicado: (2020)

NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target
por: Andraos, Elissa, et al.
Publicado: (2021)

From circRNAs to fusion circRNAs in hematological malignancies
por: Babin, Loelia, et al.
Publicado: (2021)

De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells
por: Babin, Loélia, et al.
Publicado: (2022)

Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement
por: Rigaud, Charlotte, et al.
Publicado: (2022)

Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas
por: Hoareau-Aveilla, Coralie, et al.
Publicado: (2017)

Inhibition of Rac controls NPM–ALK-dependent lymphoma development and dissemination
por: Colomba, A, et al.
Publicado: (2011)

Long non-coding RNA exploration for mesenchymal stem cell characterisation
por: Riquier, Sébastien, et al.
Publicado: (2021)

The Dual Role of Autophagy in Crizotinib-Treated ALK(+) ALCL: From the Lymphoma Cells Drug Resistance to Their Demise
por: Espinos, Estelle, et al.
Publicado: (2021)

Generation of full-length circular RNA libraries for Oxford Nanopore long-read sequencing
por: Fuchs, Steffen, et al.
Publicado: (2022)

Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma
por: Stadler, Serena, et al.
Publicado: (2018)

Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
por: Wang, Yuan, et al.
Publicado: (2022)

Kmerator Suite: design of specific k-mer signatures and automatic metadata discovery in large RNA-seq datasets
por: Riquier, Sébastien, et al.
Publicado: (2021)

Pathobiology of ALK-negative anaplastic large cell lymphoma
por: Pileri, Stefano A., et al.
Publicado: (2011)

ALK-positive anaplastic large cell lymphoma in adults
por: Gromowsky, Matthew J, et al.
Publicado: (2023)

An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive
por: Turner, Suzanne D.
Publicado: (2017)

Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
por: Nakajima, Masayuki, et al.
Publicado: (2016)

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
por: van Erp, Anke E. M., et al.
Publicado: (2017)

Prevalence of CD30 immunostaining in neoplastic mast cells: A retrospective immunohistochemical study
por: Russano de Paiva Silva, Geisilene, et al.
Publicado: (2018)

ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma
por: Tabbó, Fabrizio, et al.
Publicado: (2012)

Educational Case: ALK-Negative Anaplastic Large Cell Lymphoma
por: Satou, Akira, et al.
Publicado: (2020)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
por: Subbiah, V., et al.
Publicado: (2021)

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
por: Iwama, Eiji, et al.
Publicado: (2014)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019)

Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels
por: Duijkers, Floor A. M., et al.
Publicado: (2011)

From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL)
por: Werner, Michael T., et al.
Publicado: (2017)

NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma
por: Haque, Moinul, et al.
Publicado: (2019)

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma
por: Singh, Vijay Kumar, et al.
Publicado: (2019)

Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
por: Zdzalik, Daria, et al.
Publicado: (2014)

Molecular diagnosis of T-cell lymphoma: a correlative study of PCR-based T-cell clonality assessment and targeted NGS
por: Syrykh, Charlotte, et al.
Publicado: (2021)

Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma
por: Krishnamurthy, Savitri, et al.
Publicado: (2013)

ALK-positive anaplastic large cell lymphoma that presented as pleural effusion
por: Kim, Do Hwan, et al.
Publicado: (2022)

ALK-Positive Anaplastic Large Cell Lymphoma Associated With Hemophagocytic Lymphohistiocytosis
por: Chao, Shing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hfcfrsc74bbdoa3hp4686o038o